Lepu Biopharma's EGFR ADC Vebercotatug Receives NMPA Approval; Asymchem Reports 13.46% YoY Decline in Q3 Net Profit
LEPU BIOPHARMA
Innovative Oncology Treatment Product Developer
ASYMCHEM
Pharmaceutical R&D and Production Outsourcing Service Provider
RemeGen
Biological New Drug Developer
olymvax
Human Vaccine Research and Development Manufacturer
Simnova
Innovative Cell Therapy Product Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
A New Historical Moment for ADCs Made in China.
On October 30, according to the NMPA website, LEPU BIOPHARMA's EGFR ADC injection, Vericetuzumab (MRG003), was approved for marketing in China. It is indicated for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapy.
CXO Star Company Releases Q3 Report.
On October 30, ASYMCHEM released its Q3 financial report for 2025. In the third quarter, the company achieved operating revenue of 1.442 billion yuan, a year-on-year decrease of 0.09%; net profit attributable to shareholders of the listed company was 183 million yuan, a year-on-year decrease of 13.46%. For the first three quarters, operating revenue reached 4.630 billion yuan, a year-on-year increase of 11.82%; net profit attributable to shareholders of the listed company was 800 million yuan, a year-on-year increase of 12.66%.
In the past day, what are the hotspots in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Aji Jun take you to explore.
/ 01 /
Capital Information
1) ASYMCHEM's Q3 Net Profit Decreased by 13% Year-on-Year
On October 30, ASYMCHEM released its Q3 financial report for 2025. In the third quarter, the company achieved operating revenue of 1.442 billion yuan, a year-on-year decrease of 0.09%; net profit attributable to shareholders of the listed company was 183 million yuan, a year-on-year decrease of 13.46%. For the first three quarters, operating revenue reached 4.630 billion yuan, a year-on-year increase of 11.82%; net profit attributable to shareholders of the listed company was 800 million yuan, a year-on-year increase of 12.66%.
2) RemeGen's revenue in the first three quarters was 1.72 billion yuan, a year-on-year increase of 42.3%.
On October 30, RemeGen released its Q3 financial report for 2025. In the third quarter, the company achieved a revenue of 620 million yuan, with a total income of 1.72 billion yuan in the first three quarters, representing a year-on-year increase of 42.3%.
/ 02 /
Pharmaceutical News
1) LEPU BIOPHARMA's EGFR ADC Approved for Marketing
On October 30, according to the NMPA website, LEPU BIOPHARMA's EGFR ADC injection, Vericetuzumab (MRG003), was approved for marketing in China. It is indicated for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor treatments.
2) Olymvax's Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) Initiates Phase III Clinical Trial
On October 30, Olymvax announced that the company's Quadrivalent Influenza Virus Split Vaccine (MDCK cell) has initiated Phase III clinical trials and completed the enrollment of the first subject. The vaccine is intended for individuals aged 6 months and above to prevent influenza caused by vaccine-related strains of the influenza virus.
3) Simnova's SNC115 Injection Receives Clinical Approval
On October 30, according to the CDE official website, Simnova's SNC115 injection received clinical approval for use in patients with relapsed or refractory small cell lung cancer and relapsed or refractory other neuroendocrine cancers.
4) Simnova's VPD/FC01002 Injection Receives Clinical Approval
On October 30, according to the CDE official website, VPD/FC01002 Injection from Weineng Life received clinical approval and is proposed for the study of treating diabetic nephropathy.
5) Lilly's Lebrikizumab Injection Receives Clinical Approval
On October 30, according to the CDE official website, Eli Lilly's Lebrikizumab injection received clinical approval and is proposed for use in perennial allergic rhinitis (PAR).
PS: Welcome to scan the QR code below to add Aminochem's WeChat account for communication.
